VELCADE 3.5 MG I.V FLC

Velcade (bortezomib) is a medication used primarily in the treatment of multiple myeloma and mantle cell lymphoma. The formulation you mentioned, Velcade 3.5 mg I.V. FLC, indicates that it is a single-dose vial (flask) of bortezomib for intravenous (I.V.) administration, containing 3.5 mg of the active ingredient. Bortezomib is classified as a proteasome inhibitor. It works by interfering with the normal function of proteasomes, which are structures within cells responsible for breaking down proteins. By inhibiting proteasomes, bortezomib disrupts the process of protein degradation, leading to the accumulation of proteins that are toxic to cancer cells and ultimately causing their death. The specific dosage and treatment regimen of Velcade depend on factors such as the type and stage of cancer being treated, the patient’s overall health, and other medications they may be taking. Velcade is typically administered under the supervision of a healthcare professional experienced in the use of chemotherapy drugs, and the dosage and administration schedule may vary based on individual patient needs. It’s essential to follow your healthcare provider’s instructions carefully when receiving Velcade chemotherapy to ensure optimal treatment outcomes and minimize potential side effects. If you have any questions or concerns about Velcade or its use, be sure to discuss them with your doctor or healthcare provider.